Antonio T. Baines

TL;DR: An overview of past and ongoing strategies to inhibit oncogenic Ras in cancer is presented and genome-wide unbiased genetic screens have identified novel directions for future anti-Ras drug discovery.

TL;DR: RalGEFs were recently shown to be critical for Ras-mediated transformed and tumorigenic growth of human cells, and it is shown that the oncogenic activity of these proteins is propagated by activation of one RalGEF substrate, RalA, but blunted by another closely related substrate,RalB, and that theoncogenic signaling requires binding of the RalBP1 and exocyst subunit effector proteins.

TL;DR: Investigation of student learning outcomes using a case‐based approach focused on cellular respiration found students who used the case study exhibited a significantly greater learning gain, and demonstrated use of higher‐order thinking skills.

TL;DR: It is shown that Pim-1 is required for PDAC cell growth, invasion and radioresistance downstream of oncogenic K-Ras, and this work helps elucidate the role of PIM-1 in PDAC growth transformation and validate Pin-1 kinase as a potential molecular marker for mutated K- Ras activity.

TL;DR: Combining drug therapies that inhibit Pim kinases, such as Pim-3, with chemotherapeutic agents, to aid in decreasing chemoresistance in pancreatic cancer are suggested.